Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Lamivudine in HBeAg-Negative Chronic Hepatitis B
NCT00035789Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2001
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Histologic Improvement (Knodell Score) at 48 weeks. Started Nov 2001; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00035789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035789.